11/26/2021, 3:35 PM (Source: TeleTrader)
more TeleTrader news


Chart for: MERCK KGAA O.N.

Merck revises down its COVID-19 drug efficacy

Merck & Co. Inc. and Ridgeback Biotherapeutics released on Friday an update on the study of their COVID-19 treatment molnupiravir, stating it reduces the risk of hospitalization or death by 30%. Previously, the companies reported an efficacy of 50% in an interim analysis.

"The interim analysis and the additional analyses support the efficacy and overall favorable benefit-risk assessment of molnupiravir for the treatment of mild to moderate COVID-19 in adults at high risk for disease progression," Merck and Ridgeback maintained. The drug has been authorized for use in the United Kingdom and is under review in the United States and the European Union.

Baha Breaking News (BBN) / DJ